Last week CNN published an investigative report that concluded that Avanir Pharmaceuticals was paying physicians to prescribe its drug, Neudexta, to Alzheimer’s patients under the pretext that these patients have a rare disease. CNN’s research revealed a 400% increase in the sale of Neudexta in the past four years, and Read More…
STAT, the on-line health publication covering medicine, science and health issues, recently sponsored an hour on-line “chat” with Reisa Sperling, the head of the Center for Alzheimer’s Research and Treatment at Brigham & Women’s Hospital. Dr. Sperling answered questions about the state of Alzheimer research and STAT reporters filled out Read More…
The discouraging truth is that there is no cure for Alzheimer’s in sight. Drugs that have shown some promise, and theories about the influence of exercise, sleep, and diet on disease progression await further research. While there are many reasons why progress has been slow, one factor is the difficulty Read More…
Millions of dollars are being spent on research efforts to find a treatment for Alzheimer’s disease. These efforts are hampered by the inability to definitively identify who has early stage Alzheimer’s disease, or who might be Read More…
The press reports the results of clinical trials, but the reports rarely explain what is involved in conducting a clinical trial. Clinical trials test drugs on human subjects to determine if they are safe for humans to take, and whether they are effective in slowing, preventing or reversing the course of a disease. Read More…
